# Clinical Trials Data KIT - Document 17

# Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia

## Clinical Trial: https://clinicaltrials.gov/study/NCT01066286

"eligibilityCriteria": "Inclusion Criteria:\n\n\* patients with core binding factor positive acute myeloid leukemia\n\* 18 years or older\n\* patients were treated with standard chemotherapy\n\* patients with available medical record and stored bone marrow specimen at time of diagnosis\n\nExclusion Criteria:\n\n\* no definive criteria",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "core binding factor positive acute myeloid leukemia",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial description \*\*does not mention KIT mutations specifically\*\*, either as an inclusion or exclusion criterion. Therefore, we \*\*cannot determine\*\* from this information alone whether a patient with a KIT mutation would be eligible. Having a KIT mutation might not affect eligibility either way. More information is needed.